21:21 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
22:09 , Apr 12, 2018 |  BC Extra  |  Company News

Management tracks: Verona, Medigene, NeoPhore

Respiratory disease company Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said CMO Kenneth Newman will resign, effective April 30. The company is seeking a successor. Cancer immunotherapy company Medigene AG (Xetra:MDG1) said CMO and SVP Kai Pinkernell...
07:00 , May 11, 2009 |  BC Week In Review  |  Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) is no longer required to pay milestones to BioAxone under a 2006 deal that granted Alseres exclusive, worldwide rights to BioAxone's Cethrin . In return, Alseres has an...
07:00 , Oct 9, 2008 |  BC Innovations  |  Targets & Mechanisms

In the mood for regeneration

Researchers at the University of Texas Southwestern Medical Center have found that lithium, the marketed mood stabilizer, might have utility in spinal cord injury, an indication for which there are no approved drugs. 1 In...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Clinical News

Cethrin regulatory update

The EC granted Orphan Drug designation for Cethrin to treat traumatic spinal cord injury (SCI). The recombinant C3 exoenzyme protein, a Rho GTPase antagonist, mixed with a fibrin sealant also has Orphan designation in the...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Clinical News

Cethrin: Phase IIb start

In 1Q09, Alseres will begin a double-blind, placebo-controlled, North American Phase llb trial (ALSE-C-01) in about 50 patients. The study was initially slated to begin in 1H08. The company has an exclusive worldwide license to...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

Cethrin: Phase I/IIa data

Twelve-month data from an open-label, North American Phase I/lla trial showed that 5 of 13 (38%) patients with cervical injury had a 2-grade or better improvement in the American Spinal Injury Association (ASIA) Impairment Scale...
07:00 , May 12, 2008 |  BC Week In Review  |  Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) received an option to pay a fee in return for reducing the amount of potential milestones and royalties due to BioAxone under a 2007 deal to develop BioAxone’s...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Clinical News

Cethrin: Phase I/IIa expanded

ALSE expanded an open-label, dose-escalation, U.S. and Canadian Phase I/IIa trial to evaluate 9 mg of Cethrin in patients with cervical SCI. The protocol modification is based on safety analyses of data from the initial...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

Cethrin: Phase I/IIa ongoing

ALSE (formerly Boston Life Sciences Inc. ) said FDA approved a protocol change for an ongoing open-label, dose-escalation, North American Phase I/IIa trial to increase the dose level of cethrin to 9 mg. Previous dose...